AC Immune
ACIU • NASDAQ
AC Immune is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Andrea Pfeifer, with a market cap of $274.8M.
CEOAndrea Pfeifer
Next Earnings
Upcoming earnings announcement for AC Immune
Date
Wednesday, April 29, 2026 (in 4 weeks)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.20
Revenue Estimate
$1.0M
Earnings History
Past 12 earnings reports for AC Immune
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 13, 2026 | Q4 2025 | -$0.18Est: -$0.19 | +7.9% | $422.9KEst: $2.3M | -81.6% | — |
| Nov 4, 2025 | Q3 2025 | -$0.20Est: -$0.22 | +9.1% | $1.2MEst: $1.5M | -22.8% | — |
| Aug 5, 2025 | Q2 2025 | -$0.25Est: -$0.20 | -25.0% | $1.5MEst: $3.7M | -58.5% | — |
| Apr 30, 2025 | Q1 2025 | -$0.21Est: -$0.21 | 0.0% | $1.1MEst: $335.6K | +228.1% | — |
| Mar 13, 2025 | Q4 2024 | -$0.18Est: -$0.19 | +5.3% | $1.3MEst: $556.4K | +132.9% | — |
| Nov 5, 2024 | Q3 2024 | $0.06Est: -$0.23 | +126.1% | $29.4MEst: $1.7M | +1592.1% | — |
| Aug 6, 2024 | Q2 2024 | -$0.25Est: $0.31 | -180.6% | $759.6K | — | — |
| May 13, 2024 | Q1 2024 | -$0.21Est: -$0.15 | -40.0% | -Est: $6.1M | -100.0% | — |
| Mar 14, 2024 | Q4 2023 | -$0.06Est: -$0.13 | +53.8% | $16.7MEst: $11.4M | +45.9% | — |
| Nov 3, 2023 | Q3 2023 | -$0.20 | — | - | — | — |
| Aug 4, 2023 | Q2 2023 | -$0.22Est: -$0.22 | 0.0% | -Est: $1.9M | -100.0% | — |
| Apr 28, 2023 | Q1 2023 | -$0.23Est: -$0.25 | +8.0% | - | — | — |